NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

Verastem logo
$6.86 -0.01 (-0.15%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$6.98 +0.11 (+1.68%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Verastem Stock (NASDAQ:VSTM)

Advanced

Key Stats

Today's Range
$6.81
▼
$7.20
50-Day Range
$6.86
▼
$10.10
52-Week Range
$3.43
▼
$10.82
Volume
3.72 million shs
Average Volume
3.23 million shs
Market Capitalization
$864.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.83
Consensus Rating
Moderate Buy

Company Overview

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway.

The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.

AI Generated. May Contain Errors.

Verastem Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

VSTM MarketRank™: 
2.155837004405 of 5 stars

Verastem scored higher than 43% of companies evaluated by MarketBeat, and ranked 593rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verastem has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Verastem has a consensus price target of $16.83, representing about 145.4% upside from its current price of $6.86.

  • Amount of Analyst Coverage

    Verastem has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verastem's stock forecast and price target.
  • Earnings Growth

    Earnings for Verastem are expected to decrease in the coming year, from ($1.88) to ($2.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verastem is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verastem is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verastem has a P/B Ratio of 85.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    22.15% of the float of Verastem has been sold short.
  • Short Interest Ratio / Days to Cover

    Verastem has a short interest ratio ("days to cover") of 5.17.
  • Change versus previous month

    Short interest in Verastem has recently increased by 14.34%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Verastem does not currently pay a dividend.

  • Dividend Growth

    Verastem does not have a long track record of dividend growth.

  • News Sentiment

    Verastem has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Verastem this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $386,390.00 in company stock.

  • Percentage Held by Insiders

    1.94% of the stock of Verastem is held by insiders.

  • Percentage Held by Institutions

    88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verastem's insider trading history.
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VSTM Stock News Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Verastem (NASDAQ:VSTM) CEO Sells $12,470.40 in Stock
See More Headlines

VSTM Stock Analysis - Frequently Asked Questions

Verastem's stock was trading at $7.72 at the beginning of the year. Since then, VSTM stock has decreased by 11.1% and is now trading at $6.86.

Verastem, Inc. (NASDAQ:VSTM) posted its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.27. The biopharmaceutical company earned $24.01 million during the quarter, compared to the consensus estimate of $26.57 million. Verastem had a negative net margin of 178.38% and a negative trailing twelve-month return on equity of 359.49%.
Read the conference call transcript
.

Verastem shares reverse split before market open on Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Verastem (VSTM) raised $45 million in an initial public offering (IPO) on Friday, January 27th 2012. The company issued 4,500,000 shares at a price of $9.00-$11.00 per share.

Verastem's top institutional investors include State Street Corp (4.44%), Nantahala Capital Management LLC (1.97%), Goldman Sachs Group Inc. (1.15%) and AIGH Capital Management LLC (1.24%). Insiders that own company stock include Dan Paterson, Daniel Calkins, Brian M Stuglik, Robert E Gagnon, Michael Kauffman and Paul A Bunn.
View institutional ownership trends
.

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Novavax (NVAX), Advanced Micro Devices (AMD), Plug Power (PLUG) and Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VSTM
CIK
1526119
Fax
N/A
Employees
102
Year Founded
2010

Price Target and Rating

High Price Target
$24.00
Low Price Target
$12.00
Potential Upside/Downside
+145.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$209.47 million
Net Margins
-178.38%
Pretax Margin
-177.56%
Return on Equity
-359.49%
Return on Assets
-78.60%

Debt

Debt-to-Equity Ratio
11.19
Current Ratio
1.93
Quick Ratio
1.91

Sales & Book Value

Annual Sales
$30.91 million
Price / Sales
27.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
85.75

Miscellaneous

Outstanding Shares
126,010,000
Free Float
123,570,000
Market Cap
$864.43 million
Optionable
Optionable
Beta
0.45

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:VSTM) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners